Travere Therapeutics (TVTX) Revenue (2014 - 2026)

Travere Therapeutics has reported Revenue for 13 years, with the latest figure at $127.2 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 55.63% year-over-year to $127.2 million; the trailing twelve-month figure through Mar 2026 stood at -$70.1 million (down 125.62% YoY), and the FY2025 full-year result was $9.3 million, down 96.01% from the prior year.
• Revenue for Q1 2026 stood at $127.2 million, up from -$351.7 million in the prior quarter.
• The five-year high for Revenue was $127.2 million in Q1 2026, with the low at -$351.7 million in Q4 2025.
• Historically, Revenue has averaged $29.4 million across 5 years, with a median of $40.0 million in 2025.
• Annual changes were most pronounced in 2022 — Revenue soared 118.54% — and 2025, when it slumped 570.32%.
• Travere Therapeutics' Revenue stood at $29.3 million in 2022, then jumped by 53.58% to $45.1 million in 2023, then surged by 65.98% to $74.8 million in 2024, then tumbled by 570.32% to -$351.7 million in 2025, then surged by 136.16% to $127.2 million in 2026.
• The last three Revenue figures came in at $127.2 million (Q1 2026), -$351.7 million (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.